On February 5, 2024, Novo Nordisk A/S announced it will acquire three fill-finish manufacturing sites from Novo Holdings A/S for $11 billion to enhance production capacity. This acquisition aims to better serve diabetes and obesity patients, incrementally increasing capacity starting in 2026.